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ABSTRACT 
Objective: To assess the rationale use of benzodiazepines among various departments in a multi-speciality hospital. 
Methods: A prospective study was conducted with a sample size of 200 for a period of six months. Data was collected from patients based on 
inclusion and exclusion criteria. Naranjo Adverse Drug Reaction Probability Scale and Drug Interaction Probability Scale (DIPS) were used as a 
study tool to measure the causality of adverse drug reactions and drug interactions. Based on the dosage of various benzodiazepines DDD was 
calculated and compared with WHO Anatomical Therapeutic Chemical (ATC) classification Defined Daily Dose (DDD). 
Results: BZD’s were mostly prescribed in males (74.5%) and married patients (86.5%) were more exposed to benzodiazepines compared to others. 
Lorazepam (70.1%) was found to be the most commonly used drug, mainly prescribed for sedation, followed by anxiety. DDD was calculated and 
majority of patients had DDD in accordance with WHO standard. Based on cost analysis, Clobazam was found to be the high cost and Lorazepam 
being the low-cost drug. The results of drug utilization evaluation of benzodiazepines study were compiled and reported to the respected 
department physician and their feedback was collected. 
Conclusion: The study showed a rational utilization of benzodiazepines and the negative outcomes of BZDs can be reduced by providing drug-
related information to the prescribers and consumers. 
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Drug utilization studies are used as a potential tool in the evaluation of 
health care system which has been conducted and major problems 
with respect to drug use patterns, prescribing behavior, gaps between 
guidelines were addressed. Benzodiazepines have long been used for 
conditions including various psychiatry disorders, insomnia, acute 
alcohol withdrawal and epilepsy [1]. Such studies help in optimizing 
the rational use of drugs in a clinical setting [2]. 
DUE implies the prescription of a well-documented drug in an 
optimal dose on the right indication, with correct information and at 
an affordable price. It also provides insight into the efficacy of drug 
use i.e. whether a certain drug therapy provides value for money.  
Benzodiazepines (BZD) have become one of the most commonly 
prescribed classes of drugs due to their multiple therapeutic actions 
such as anxiolytics, sedatives, seizures, muscle relaxants and 
dependence syndrome [3]. 
Epidemiologic data from Europe, Canada, Japan and Australia indicate 
that rates of benzodiazepine use in the general population were found 
to be around 6%. It is reported that BZDs are often prescribed without 
any appropriate documentation for its use in the patients [3]. 
Off-label use is common in psychiatric patients where Clonazepam 
and lorazepam were reported to be the most frequently used drugs 
in an off-label manner [4]. 
One major explanation for the misuse of Benzodiazepines in the 
current scenario is lack of specific information regarding the adverse 
outcome of benzodiazepines and also about alternatives such as 
non-benzodiazepines sedatives [5]. BZDs are associated with 
various adverse effects either with long term or short term use and 
also the higher incidence of drug-drug interactions was reported 
among psychiatric patients [5, 6]. 
With limited duration and in lower doses, benzodiazepines usage 
was correlated with the improvement in the quality of life of the 
patients [7]. The present study aimed to assess the rationale of BZD 
usage by evaluating the prescription pattern and drug-related 
problems among various departments in a multi-speciality hospital. 
MATERIALS AND METHODS 
Study site 
The study was conducted at PSG Hospitals, Peelamedu, Coimbatore. 
Study approval 
This study was approved by the Institution Human Ethics 
Committee (IHEC, PSG IMSR) of the hospital. The protocol was 
approved on 16/08/2018, Proposal number: 15/081. Patients or 
caretakers who were not willing to give informed consent were 
excluded from the study. 
Study design 
A prospective study of Drug Utilization Evaluation of 
Benzodiazepines was conducted to evaluate the prescription 
pattern, drug-related problems, indication, dose of the drugs and to 
assess the drug usage pattern using DDD. 
Study period 
The study was conducted for a period of 6 mo. 
Study subjects 
Various departments such a General Medicine, Cardiology, 
Gastroenterology, Psychiatry, Neurology, and Orthopedics were 
included in the study. Patients who were in the age group 20-80, 
prescribed with any formulation of benzodiazepines and were able 
to communicate were considered as an inclusion criteria, whereas 
pediatrics and outpatients were excluded from the study.  
Data collection 
Patients were approached in the respected departments based on 
the inclusion and exclusion criteria. After explaining about the study 
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in a regional language, consent form was collected from the patients 
prior to data collection. Data regarding the socio-demographic and 
clinical characteristics of the patients were obtained through 
interviews and past medical records.  
From the drug chart review, current medications along with dosage, 
frequency, route of administration and duration of therapy have been 
recorded and assessed for drug interactions, adverse drug reactions, 
contraindications and also for the cost of the benzodiazepines therapy 
during the hospital stay. Follow up of patients will be continued till the 
patient is on BZD therapy during hospitalization or till discharge. 
 
(Nachiya et al., 2015) [8] 
RESULTS 
The study was conducted among 200 patients based on the inclusion 
and exclusion criteria. 
Table 1 shows the baseline characteristics. The gender-wise 
distribution shows that out of 200 patients, 74.5% were male and 
25.5% were female. Social habit depicts 25% were alcoholics, 7.5% 
were smokers, and 15.5% were both smoker and alcoholic. Married 
patients made up 86.5% of the total benzodiazepine prescribed 
population. Benzodiazepine prescription was more common among 
the employed patients which were 56.5% when compared to the 
unemployed.
  
Table 1: Baseline characteristics 
Characteristics No of patients (n) Percentage (%) P value 
Gender    
Male 149 74.5 0.001 
Female 51 25.5  
Social habits    
Smoker 15 7.5 0.03 
Alcoholic 50 25  
Both 31 15.5  
None 104 52  
Marital status    
Single 
 
25 12.5 0.796 
Married 173 86.5  
Others 2 1  
Employment    
Employed 113 56.5 0.032 
Unemployed 87 43.5  
 
In table 2 pattern of benzodiazepines usage is illustrated in 
which 70.1% were prescribed with lorazepam. Among six 
departments, cardiology department was found to have more 
benzodiazepine usage which was 44.5%. The most common 
clinical condition of patients treated with benzodiazepines was 
sedation, which was 40.3% followed by 36.3% of anxiety. 81.6% 
of patients did not develop any adverse drug reactions which 
were a high proportion while 18.4% developed ADRs. Drug 
interactions were not found in majority of the patients which 
showed 81.6%. 
 















Department, n (%)        
Cardio 87(43.2) 1(0.5) 0(0) 1(0.5) 0(0) 0(0) 89(44.5) 0.000 
Ortho 0(0) 0(0) 0(0) 2(1) 0(0) 0(0) 2(1) 
Psych 31(15.3) 5(2.5) 17(8.5) 1(0.5) 1(0.5) 2(1) 57(28.5) 
Gen. Med 8(4) 3(1.5) 1(0.5) 0(0) 0(0) 0(0) 12(5.5) 
Neuro 6(3) 3(1.5) 3(1.5) 3(1.5) 0(0) 8(4) 23(11.5) 
Gastro 9(4.5) 0(0) 4(2) 5(2.5) 0(0) 0(0) 18(9) 
Clinical condition, n(%)       
Sedation 65(32.3) 2(1) 9(4.5) 3(1.5) 0(0) 2(1) 81(40.3) 0.000 
Anxiety 44(21.9) 4(2) 11(5.5) 9(4.5) 1(0.5) 4(2) 73(36.3)  
Insomnia due to 
anxiety 
22(10.9) 0(0) 1(0.5) 0(0) 0(0) 0(0) 23(11.4)  
Seizure 0(0) 0(0) 4(2) 0(0) 0(0) 4(2) 8(4)  
ADS 10(5) 6(3) 0(0) 0(0) 0(0) 0(0) 16(8)  
Drug related problems of BZDs:      
ADR, n(%)        
Definite 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0.000 
Probable 2(1) 1(0.5) 0(0) 0(0) 1(0.5) 2(1) 6(3)  
Possible 25(12.4) 1(0.5) 2(1) 1(0.5) 0(0) 1(0.5) 30(15)  
Doubtful 0(0) 0(0) 1(0.5) 0(0) 0(0) 0(0) 1(0.4)  
Nil 114(56.7) 10(5) 22(11) 11(5.4) 0(0) 7(3.5) 164(81.6)  
Drug Interactions, n(%)        
Highly probable 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.001 
Probable 6 (3) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.5) 7 (3.5)  
Possible 13 (6.5) 1 (0.5) 6 (3) 5 (2.5) 0 (0) 4 (2) 29 (14.4)  





19 (9.5) 7 (3.5) 1 (0.5) 4 (2) 164(81.6)  
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Table 3 shows the mean and median of benzodiazepines defined daily 
dose. In our study, the mean DDD of patients taking lorazepam 2 mg was 
found to be 2.6 which was exceeded when compared to the standard 
DDD which is 2.5. Similarly, the mean DDD of diazepam 10 mg was 
exceeded to 30 than the standard (10). 90 patients were prescribed with 
benzodiazepines in accordance with the WHO ATC standard. 
 
Table 3: Mean and median of benzodiazepines defined daily dose 
Drugs Dose (mg) n(%) WHO ATC DDD (mg) Mean DDD in mg(DDD) Median DDD in mg(DDD) 
Lorazepam 1  47(52.3) 2.5 1.4(0.57) 1(0.4) 
 2 19(21.2) 2.5 2.6(1.045) 2(0.8) 
Chlordiaze-poxide 10  2(2.2) 30 20(0.67) 20(0.67) 
 20  2(2.2) 30 20(0.67) 20(0.67) 
Clonazepam 0.5  5(5.5) 8 0.46(0.06) 0.48(0.06) 
 1 1(1.1) 8 2(0.25) 2(0.25) 
Alprazolam 0.25  2(2.2) 1 0.25(0.25) 0.25(0.25) 
 0.5  7(7.8) 1 0.52(0.52) 0.5(0.5) 
Diazepam 10  1(1.1) 10 30(3) 30(3) 
Clobazam 5  1(1.1) 20 5(0.25) 5(0.25) 
 10  3(3.3) 20 18.5(0.92) 18(0.89) 
 
In table 4, Patients were divided into 2 groups, BZD prescription 
below 5 d and above 5 d. Under each group, mean dose of various 
generics of BZDs were calculated and compared between patients 
with ADR and without ADR in which positive correlation (p= 0.017) 
was observed with Lorazepam taking patients less than 5 d and 
negative correlation was observed in patients taking 
chlordiazepoxide and clobazam for more than 5 d and clonazepam 
less than 5 d. 
 
Table 4: Comparison of ADRs based on mean dose of various generics of BZDs 
Drug 5 D Above 5 D 
n (%) ADR at dose 
(mg) 
n (%) No ADR 
at dose 
(mg) 
p value n (%) ADR 
at dose 
(mg) 
n (%) No ADR 
at dose (mg) 
p value 
Lorazepam 19(9.5) 5.105 75(37.3) 4.973 0.017 8(4) 15.125 39(19.4) 11.897  0.130 
Chlordiazepoxide 0(0) 0 7(3.4) 58.57 - 2(1) 60 3(1.5) 173.33 -0.688 
Clonazepam 2(1) 1.5 16(8) 2.187 -0.266 1(0.5) 14 6(3) 4.42 0.946 
Alprazolam 0(0) 0 6(3) 1.5 - 1(0.5) 5 5(2.4) 3.15 0.389 
Clobazam 2(1) 40 3(1.5) 21.67 0.809 1(0.5) 80 4(2) 272.5 -0.570 
 
Fig. 1 depicts the appropriateness of benzodiazepines based on 
defined daily dose were 55% had DDD more than the standard, 
38.5% had DDD less than or equal to standard and DDD was not 
calculated for 6.5% patients. 
 
 
Fig. 1: Appropriateness of BZD’s based on DDD 
 
DISCUSSION 
A study on drug utilization evaluation of benzodiazepines was 
conducted in a multi-speciality hospital to assess the rational use of 
benzodiazepines among 200 patients. In our study, benzodiazepines 
are prescribed more in males than in females, which is significant 
(p= 0.001) and the percentage of BZD was more in alcoholics [9]. 
These results were similar to the previous studies whereas a 
contrast to this was observed where the rate of benzodiazepine use 
was higher among women than men [15]. 
In our study BZDs were prescribed more in the married population 
as it is observed that married people undergoes more mental 
pressure than others [7]. The prescription of BZDs found to be 
higher in Cardio patients followed by psychiatry, as cardio patients 
are more likely to be anxious and restless about their condition 
illustrating the scientific rationale for BZD usage in people with 
heart disease. Lorazepam is the most commonly prescribed BZD in 
patients owing to its short-acting activity, which also improves both 
the emotional status and quality of life in patients. 
The present study shows that BZD was mostly used for sedation 
followed by anxiety condition which is a contrast to the study 
conducted in 2016 in which BZDs were mainly used for anxiety 
(44.4%)[10,16]. As majority of patients in the present study were from 
cardiology department, insomnia may contribute as a risk factor for 
developing high blood pressure, CHD and heart failure [11]. Overall, 
64.1% patients were prescribed with 4 to 6 d of BZDs and the BZD 
prescription increases with the lengthening of hospital stay. 
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Table 2 shows that 18.4% of patients have developed ADR such as 
drowsiness and dizziness. ADRs were frequently found in patients 
taking Lorazepam which was similar to the previous study as it 
results in the direct extension of CNS depressant properties [12, 
13]. Interventions were made through clinical pharmacists in 11% 
of patients by stopping the drug in 8% and by dose reduction in 
3%. 
On assessing the Drug-interaction, it depicts that interactions were 
identified in 18.5% patients where Lorazepam showed a higher rate 
of drug interactions which was identical to the previous study [14]. 
Out of 200 patients, only one patient was admitted with BZD 
dependence syndrome and was treated with long acting BZD 
(Diazepam) during our study period. 
DDD per patient is calculated in patients prescribed with BZDs for 
its main indication as anxiolytics and anti-epileptics. Considering 
WHO ATC DDD as a standard reference, it showed 38.5% of 
patients were prescribed in accordance with that and 6.5% of 
patients showed inappropriate use (exceeded the standard DDD), 
fig. 1. 
From table 3, it is found that DDD of patients who were taking 
Lorazepam 2 mg (2.6 mg) exceeded the standard DDD (2.5 mg) 
which can be avoided by dose reduction. The mean and median of 
DDD/patient was found to be 5.64 and 2. In an average hospital stay 
of 6 d a patient was exposed to 5.64 DDD’s which is found to be 
rational.  
The study shows that benzodiazepines were continued after 
discharge in 31.3%. Drug related problems during discharge were 
analyzed in which 5.47% had developed ADR and 6% had drug-drug 
interactions during their hospital stay.  
Table 4 shows that patients who are taking lorazepam less than 5 d 
found to be significant(p= 0.017) on positive correlation whereas 
insignificant result was seen in more than 5 d of Clonazepam, 
Alprazolam and lorazepam prescription. This depicts that ADRs are 
dose dependent in patients taking Lorazepam independent of the 
duration of BZD prescription. 
From our study, Clobazam was founds to be the high cost BZD 
compared to others. But while considering the duration of therapy, it 
showed that Chlordiazepoxide contributed 45% and Lorazepam 
being the low cost drug contributed 70.1% to the overall BZD 
prescription indicating a rational utilization of drugs. 
Through Feedbacks obtained from the physicians, it is identified 
that Lorazepam was the drug of choice followed by Alprazolam 
and Clonazepam. Benzodiazepines were prescribed as short 
term for insomnia and anxiety and as long term for alcohol 
withdrawal and seizure. 5 out of 6 physicians suggested mental 
status examination in patients before prescribing BZDs except in 
cardiology where 61.7% of BZDs were prescribed, which can be 
considered to avoid over usage. The limitation of the study was 
Defined Daily Dose was not available for all the benzodiazepines. 
CONCLUSION 
Lorazepam was founds to be the commonly prescribed drug due to 
its beneficial action compared to other benzodiazepines and its 
usage was found to be more among cardio patients for short term. 
Dose dependent ADR was significantly identified in patients taking 
Lorazepam. More studies are required to validate this causation of 
dose dependent ADR in other BZDs. Drug related problems can be 
reduced with the more appropriate dose and by switching to non-
BZDs sedatives at the time of discharge. Since WHO ATC/DDD 
values are based on international data it is confined with certain 
limitations for considering it as a reference value. A safe, effective 
and optimum therapy can be provided to the patient by 
minimizing the negative outcomes and thereby ensuring the 
rationale in its use. 
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